Today, we are celebrating a series of groundbreaking advancements that mark the start of a new era for Discovery. The official opening of our brand-new state-of-the-art facilities in Huntsville, AL, and Alameda, CA, the launch of revolutionary Olink Explore HT services, and our revitalized website together will amplify our ability to empower scientists on a global scale.? ? "This trifecta of advancements signifies a profound moment in our journey," said Discovery CEO Glenn Bilawsky. "From Alameda to Huntsville, from the physical to the digital, we're reshaping the future of life sciences. We're more equipped than ever to catalyze innovations that have the potential to transform lives."? - Glenn Bilawsky, CEO of Discovery Life Sciences Visit our new website to learn more: https://lnkd.in/gHr-CZZ2
关于我们
Discovery Life Sciences, the Biospecimen and Biomarker Specialists?, is a leading provider of highly characterized human biospecimens and cellular starting materials integrated with expert multi-omic analytical services to advance cell and gene therapy and precision medicine programs for cancer, infectious disease, and other complex conditions. Our robust biospecimen and biomarker platform is optimized for speed and large scale capacity. We routinely manage hundreds of studies and expertly test thousands of biospecimens simultaneously as a single vendor - eliminating time consuming and inefficient transfers of biospecimens or data between different vendors. We offer one of the largest recallable donor pools, Research Use Only (RUO) and clinical-grade (GMP) fresh and cryopreserved human cellular materials to support cell and gene therapy programs at any scale from start to finish. Leading biopharma, diagnostic and academic institutions trust us to quickly deliver high-quality biospecimens and reliable, reproducible biomarker data, so they can outpace their competition and push the leading edge of innovation. Visit www.dls.com to learn more
- 网站
-
https://www.dls.com
Discovery Life Sciences的外部链接
- 所属行业
- 生物技术研究
- 规模
- 501-1,000 人
- 总部
- Huntsville,Alabama
- 类型
- 私人持股
- 创立
- 2018
- 领域
- human clinical samples、cancer tissues、primary cells、peripheral blood mononuclear cells、bone marrow mononuclear cells、whole blood、circulating tumor cells、lab services、blood processing、histology、pathology、protocol development、assay development、clinical targeting、sample pre-screening、data security、analytical services、tissue analysis、molecular testing、flow cytometry analysis、sample validation、quality control、genomic services和Next-Gen Sequencing
地点
Discovery Life Sciences员工
动态
-
SITC 2024 was fantastic! Check out our two posters presented by Dr. Dirk Zielinski, showcasing our latest studies in multiplex IF: Understanding the Role of the Immune Contexture in Invasion and Metastasis of Solid Tumors Using Multiplexed Immunofluorescence and Image Analysis: https://lnkd.in/evMNaPmQ Using Multiplexed Immunofluorescence and Image Analysis for Categorization of Her-2 Expressing Breast Cancers Based on Signal Transduction and Immune Cell Profiles: https://lnkd.in/ePnfEyhw Contact us if you are interested in our mIF services or collaborating with our assay development experts. #SITC2024?
-
The Discovery Year-End Sales Event is ending soon. This is your final chance to save big on a wide range of products and services. Supplies are limited and the event ends December 31, 2024!? https://lnkd.in/g2dkn3j3?
-
Make clinical trial decisions faster with Discovery’s Clinical Trial HLA Typing Services: https://lnkd.in/g_ii-PHq Our experts can generate Sanger sequencing results in just 3 days to optimize patient selection for clinical trials and use high-throughput NGS to resolve HLA-A genotyping ambiguities.?This service is performed in our CLIA-certified, CAP accredited, and GCLP compliant service laboratory. Discovery’s specialty lab services team has supported over 2000 clinical trial programs across many therapeutic areas. Discuss your project with us today.?
-
A new immunotherapy for Hodgkin lymphoma is raising survival rates to 92% while reducing long-term side effects. Read the article: https://lnkd.in/ghgrrpNj? ? In a randomized Phase 3 trial, patients treated with chemotherapy and the immunotherapy nivolumab saw survival rates 10% higher than the standard care treatment group. These impressive results have prompted the FDA to expedite review to decide if nivolumab should become the standard treatment for late-stage Hodgkin lymphoma. #Immunotherapy #Lymphoma
Immunotherapy Trial Boosts Advanced Hodgkin Lymphoma Survival
technologynetworks.com
-
We are pleased to announce that our Alameda, California site is now AABB-accredited. This internationally recognized accreditation signifies that Discovery Life Sciences adheres to globally recognized standards for optimal safety, quality, and ethical practices concerning patients, donors, and recipients of blood and cellular therapies. Our commitment to excellence encompasses every step of the process —from collection and processing to storage and distribution of hematopoietic progenitor cells (HPCs), ensuring the highest industry standards. For inquiries regarding your cell and gene therapy development needs, please contact us today. We look forward to collaborating with you. https://lnkd.in/gEChYJu3 #AABB #CellTherapy #GeneTherapy #CGT #Immunotherapies?
-
Join us at our Booth #919 on Nov 9, from 3-4pm for a 'Meet the Expert' session, featuring Dr. Marco C., Head of Scientific Affairs from Lunaphore (a Bio-Techne brand) and Dr. Dirk Zielinski from Discovery. They’ll be available to discuss multiplex imaging applications and answer questions about our Lunaphore COMETTM Hyperplex IF Services.? ? You can also schedule a private meeting with our experts here: https://lnkd.in/e2rJjhuh?? We look forward to seeing you in Houston.? #SITC2024?
-
Native American Heritage Month is a time to honor the rich history, celebrate the vibrant culture, and recognize lasting contributions of Indigenous knowledge. Many of today's medical advancements are rooted in Native American traditions, yet they often go unacknowledged. For instance, Native healers used willow bark as an ingestible pain reliever, a practice that led to the discovery of salicin, the active ingredient in modern aspirin.? Let's continue to celebrate and appreciate the diverse Indigenous influences that are woven into the fabric of our lives, from medicine to culture and beyond.? https://lnkd.in/geGRutZm? #NativeAmericanHeritageMonth #IndigenousMedicine?
-
Using CRISPR base editing and single-cell genomics, researchers from the Wellcome Sanger Institute mapped out the genetic landscape of drug resistance, categorizing cancer mutations into four key groups based on DNA changes. Read more: https://lnkd.in/eHUD8rgX? ? This new insight has the potential to guide patient stratification, improve clinical decisions, and help develop new therapies that better avoid resistance.? ? Attending ASHG this week? Stop by Discovery’s booth to meet with the team about your biospecimen, specialty lab services, preclinical, or cell and gene therapy needs!?? #Genomics #CRISPR #CancerResearch
Cancer drug resistance causes and categories identified??
sanger.ac.uk
-
An update to the poster presentation during World ADC! Don't miss Dr. Emer Clarke and Philip McCauley's presentation on Tuesday November 5th, 6:20-7:30pm in the Golden State Ballroom. Looking forward to another wonderful event!
Don’t miss our two poster presentations during the World ADC Summit from November 4-7 in San Diego: ? Payload in Antibody Drug Conjugates (ADCs) on Primitive Hematopoietic Progenitors Presented by Dr. Emer Clarke ? Biomarker Profiling of Primary Patient Cryopreserved Tissue for Development of Ex Vivo Models ? Presented by Philip McCauley #worldADC #ADC?